预测长期肝纤维化进展的分子特征用于指导抗纤维化药物研发
本研究定义并验证了预测5年内肝纤维化进展的20基因纤维化进展特征(FPS),并在独立NAFLD队列中验证(校正OR 10.93,AUC 0.86)。FPS用于评估13种候选抗纤维化药物在离体培养肝组织中的反应,以及cenicriviroc在临床试验患者中的反应,并开发了7蛋白血清替代FPS。
要点
- 20基因FPS可预测HCV和NAFLD患者5年内肝纤维化进展,在独立NAFLD队列验证校正OR 10.93、AUC 0.86。
- 离体评估13种候选抗纤维化药物,基于表没食子儿茶素没食子酸酯的联合方案显示增强抗纤维化效果。
- cenicriviroc治疗患者中FPS调节与1年纤维化改善相关,伴E2F通路抑制。
核心结论
- FPS以病因无关的方式预测长期纤维化进展,可指导抗纤维化药物研发。
研究设计与样本
- 定义FPS预测基线无或极轻微纤维化的丙型肝炎病毒(HCV)和非酒精性脂肪性肝病(NAFLD)患者5年内纤维化进展(n=421),并在独立NAFLD队列(n=78)验证。
- 使用FPS评估13种候选抗纤维化药物在临床纤维化肝组织离体器官型培养(n=78)中的反应,以及cenicriviroc在临床试验(NCT02217475)中 enrolled 的非酒精性脂肪性肝炎患者(n=19)中的反应。
- 开发基于血清蛋白的替代FPS并在代偿性肝硬化患者队列(n=122)中测试。
主要发现
- 20基因FPS在独立NAFLD队列中验证,校正比值比(OR)10.93,受试者工作特征曲线下面积(AUC)0.86。
- 在计算推断的纤维化驱动FPS基因中,BCL2被临床肝组织证实为潜在药理学靶点。
- 系统离体评估13种候选抗纤维化药物,识别出基于表没食子儿茶素没食子酸酯的合理联合治疗,并在临床肝组织离体培养中验证其增强抗纤维化效果。
- 接受cenicriviroc治疗的非酒精性脂肪性肝炎患者中,FPS调节与1年纤维化改善相关,伴随E2F通路抑制。
- 无纤维化改善的患者中未见PPARα通路诱导,提示联合PPARα激动剂可能改善cenicriviroc的抗纤维化疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is a major unmet need to assess the prognostic impact of antifibrotics in clinical trials because of the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. METHODS: A fibrosis progression signature (FPS) was defined to predict fibrosis progression within 5 years in patients with hepatitis C virus and nonalcoholic fatty liver disease (NAFLD) with no to minimal fibrosis at baseline (n = 421) and was validated in an independent NAFLD cohort (n = 78). The FPS was used to assess response to 13 candidate antifibrotics in organotypic ex vivo cultures of clinical fibrotic liver tissues (n = 78) and cenicriviroc in patients with nonalcoholic steatohepatitis enrolled in a clinical trial (n = 19, NCT02217475). A serum protein-based surrogate FPS was developed and tested in a cohort of compensated cirrhosis patients (n = 122). RESULTS: A 20-gene FPS was defined and validated in an independent NAFLD cohort (adjusted odds ratio, 10.93; area under the receiver operating characteristic curve, 0.86). Among computationally inferred fibrosis-driving FPS genes, BCL2 was confirmed as a potential pharmacologic target using clinical liver tissues. Systematic ex vivo evaluation of 13 candidate antifibrotics identified rational combination therapies based on epigallocatechin gallate, which were validated for enhanced antifibrotic effect in ex vivo culture of clinical liver tissues. In patients with nonalcoholic steatohepatitis treated with cenicriviroc, FPS modulation was associated with 1-year fibrosis improvement accompanied by suppression of the E2F pathway. Induction of the PPARα pathway was absent in patients without fibrosis improvement, suggesting a benefit of combining PPARα agonism to improve the antifibrotic efficacy of cenicriviroc. A 7-protein serum protein-based surrogate FPS was associated with the development of decompensation in cirrhosis patients. CONCLUSION: The FPS predicts long-term fibrosis progression in an etiology-agnostic manner, which can inform antifibrotic drug development.
引用
- Qian T, Fujiwara N, Koneru B, et al. Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology. 2021. PMID: 34951993. doi:10.1053/j.gastro.2021.12.250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。